Well, speaking of ASCO.... It's taken a while to get here, but TheraP overall survival has been released. As a reminder this trial was investigating LuPSMA treatment at an earlier stage than both VISION and LUPIN trials. In bad news for Novartis, it shows that there is no significant difference between LuPSMA and current standard of care (chemo) in terms of OS (19.1 vs. 19.6).
But, this is very interesting for NOX. The LUPIN trial gave overall survival HIGHER than TheraP at 19.7 months, even though the LUPIN cohort had much more advanced cancer.
It seems increasingly bizarre that LUPIN has not been followed up with another trial combining LuPSMA and Veyonda at earlier stages.
https://meetings.asco.org/abstracts-presentations/207021
Ann: Veyonda Abstract Published at ASCO Annual Meeting 2022, page-6
Add NOX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
8.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $23.37M | |||
| Open | High | Low | Value | Volume |
| 8.2¢ | 8.2¢ | 8.0¢ | $5.491K | 68.10K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 147568 | 8.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 8.2¢ | 30000 | 1 |
View Market Depth
| Last trade - 14.31pm 05/06/2024 (20 minute delay) ? |
|
|||||
|
Last
8.2¢ |
Change
0.000 ( 5.13 %) |
||||
| Open | High | Low | Volume | ||
| 8.2¢ | 8.2¢ | 8.2¢ | 30000 | ||
| Last updated 11.56am 05/06/2024 ? | |||||
| NOX (ASX) Chart |